Katharine Peterson
About Katharine Peterson
Katharine Peterson Education and Expertise
Katharine Peterson holds an MS in Accountancy from the University of Notre Dame and a BA in Business Economics from Providence College. She has over a decade of experience in the biotechnology industry, specializing in financial management, reporting, operational efficiencies, system rollouts, and strategic and operational planning. As a Certified Public Accountant (CPA) in the state of Massachusetts, her expertise includes extensive public accounting skills and supporting high-growth life science companies.
Katharine Peterson Finance & Accounting Career Background
Katharine Peterson began her distinguished career in the life sciences assurance practice at EY. Her professional journey continued across various roles in finance and accounting within several biotech companies. These roles include positions held at Wave Life Sciences, Spero Therapeutics, and Merrimack Pharmaceuticals. Over her career, she has gained extensive experience and proven success in public company readiness, IPO efforts, financial management, operations, technical accounting, reporting, and planning.
Katharine Peterson Role at Wave Life Sciences
Katharine Peterson currently serves as the Senior Director of Financial Planning & Analysis at Wave Life Sciences. This role involves leading the company's financial planning activities, strategic planning, and operational analysis to support the organization's growth. Her work is crucial in ensuring accurate financial reporting and the effective implementation of operational efficiencies. Her contributions support informed decision-making by the senior management team.
Katharine Peterson Public Company Readiness and IPO Contributions
Katharine Peterson has significantly contributed to the public company readiness and IPO-directed efforts for multiple small biotech companies. Her extensive background in financial management and technical accounting has equipped her with the capabilities to navigate the complex requirements of public company transitions. Through her efforts, these companies have achieved critical milestones in their growth and development within the biotechnology sector.